Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.56 |
| ▸ | SELP | P16109 | 7/20 | 0.51 |
| ▸ | MAG | P20916 | 4/20 | 0.50 |
| ▸ | SELL | P14151 | 2/20 | 0.50 |
| ▸ | SELE | P16581 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30649207 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL29369094 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL30649952 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL30650122 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL30651291 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL30651920 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL31126371 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL29359311 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL22969674 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE | |
| SCHEMBL30650374 | 1.00 | SIGLEC7 (0.56) | SIGLEC7SELPMAGSELLSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 617 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098667-A1 | USP30 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF | 长春金赛药业有限责任公司 | 2026-05-15 | — | — | WO | claimed |
| US-12616822-B2 | Cerebrospinal fluid purification system | Pharaoh Neuro, Inc. (US) | 2026-05-05 | — | — | US | claimed |
| EP-4692338-A1 | CAS12 PROTEIN AND USE THEREOF | Guangzhou Reforgene Medicine Co., Ltd. (CN) | 2026-02-11 | — | — | EP | claimed |
| EP-4595964-A1 | TREATMENT OF GM1 GANGLIOSIDOSIS | Azafaros B.V. (NL) | 2025-08-06 | — | — | EP | claimed |
| CN-120157593-A | Deuterated analogs of acetyl-leucine | 内在生物技术有限公司 | 2025-06-17 | — | — | CN | claimed |
| CN-120129680-A | Crystal forms of glucosylceramide synthase inhibitors and uses thereof | 艾司林科生物医药有限公司 | 2025-06-10 | — | — | CN | claimed |
| CN-120035662-A | Pharmaceutical composition for treating, preventing or improving GM1 ganglioside deposition or Morquio syndrome B and method of administration thereof | 新型医药公司 | 2025-05-23 | — | — | CN | claimed |
| EP-3673906-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2025-05-14 | — | — | EP | claimed |
| US-12280229-B2 | Cerebrospinal fluid purification system | NEUROFLUIDICS, INC. (US) | 2025-04-22 | — | — | US | claimed |
| CN-119790152-A | Treatment of neurological disorders using modulators of UNC13A gene transcripts | 奎里斯公司 | 2025-04-08 | — | — | CN | claimed |
| EP-4007635-A1 | COMPOSITIONS COMPRISING CHEMERIN ANALOGS AND METHODS OF USE | Okyo Pharma Limited (GG) | 2022-06-08 | — | — | EP | claimed |
| EP-4007636-A1 | COMPOSITIONS COMPRISING BOVINE ADRENAL MEDULLA 8-22 (BAM8-22) PEPTIDE ANALOGS AND METHODS OF USE | Okyo Pharma Limited (GG) | 2022-06-08 | — | — | EP | claimed |
| CN-114533729-A | Glucosylceramide synthase inhibitors | 建新公司 | 2022-05-27 | — | — | CN | claimed |
| WO-2022081567-A1 | METHODS FOR REVERSING HEPATIC STEATOSIS | BRIGHTSEED, INC. (US) | 2022-04-21 | — | — | WO | claimed |
| WO-2022071427-A1 | NEUROMUSCULAR DISEASE EVALUATION SYSTEM | 田辺三菱製薬株式会社 | 2022-04-07 | — | — | WO | claimed |
| US-20220096540-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF LYSOSOMAL STORAGE DISORDERS | BIOGRAPHENE INC. (KR) | 2022-03-31 | — | — | US | claimed |
| US-20220073959-A1 | METHODS OF GANGLIOSIDE PRODUCTION | GARNET BIOTHERAPEUTICS INC (US) | 2022-03-10 | — | — | US | claimed |
| EP-2895484-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2022-02-23 | — | — | EP | claimed |
| CN-108864076-B | Glucosylceramide synthase inhibitors | 建新公司 | 2022-02-11 | — | — | CN | claimed |
| CN-113993553-A | Treatment of lysosomal storage diseases of the eye by administration of an AAV expressing TPP1 | 费城儿童医院 | 2022-01-28 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616822-B2 | Cerebrospinal fluid purification system | AQP4, NEFM, ABCB11 | SIGLEC7 1370/4885SELP 340/4885MAG 102/4885 |
| US-20220073959-A1 | METHODS OF GANGLIOSIDE PRODUCTION | NEU2, NEU1, NEU3 | SIGLEC7 38/4885SELP 2200/4885MAG 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.